Milestone Pharmaceuticals to Present at TD Cowen Health Care Conference

MONTREAL and CHARLOTTE, N.C., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that Amit Hasija, Chief Financial Officer, and Lorenz Muller, Chief Commercial Officer, will present at the TD Cowen 46th Annual Health Care Conference, to take place March 2 - 4, 2026, in Boston.

Milestone Pharmaceuticals Inc., a biopharmaceutical company focused on developing innovative therapeutics for cardiovascular diseases, is set to present at the TD Cowen 46th Annual Health Care Conference. The event will take place virtually on March 7, 2026, where Milestone is expected to discuss its latest developments and strategic objectives.

This conference is an important platform for Milestone to connect with investors and industry stakeholders, enabling them to share insights about their pipeline products, specifically their lead product candidate, which has the potential to address significant unmet needs in the market.

During the presentation, Milestone's executives will provide a detailed overview of the company’s clinical trial results, solidifying their commitment to innovation in the healthcare space. The focus will be on engaging with a broad spectrum of audiences, including institutional investors, to enhance understanding of their strategic goals and the overall vision for the company.

The TD Cowen conference is recognized for gathering leading companies and presenting a diverse array of health care innovations, making it a key event for Milestone Pharmaceuticals to showcase its capabilities and future prospects in the competitive landscape of biopharmaceuticals.

In summary, Milestone Pharmaceuticals is poised to leverage this opportunity to enhance visibility among investors and further its mission of advancing therapeutic solutions for patients with cardiovascular conditions. The participation in this conference reflects the company's ongoing commitment to transparency and active communication with its stakeholders.